Your browser doesn't support javascript.
What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.
Turco, Fabio; Armstrong, Andrew; Attard, Gerhardt; Beer, Tomasz M; Beltran, Himisha; Bjartell, Anders; Bossi, Alberto; Briganti, Alberto; Bristow, Rob G; Bulbul, Muhammad; Caffo, Orazio; Chi, Kim N; Clarke, Caroline; Clarke, Noel; Davis, Ian D; de Bono, Johann; Duran, Ignacio; Eeles, Ros; Efstathiou, Eleni; Efstathiou, Jason; Evans, Christopher P; Fanti, Stefano; Feng, Felix Y; Fizazi, Karim; Frydenberg, Mark; George, Dan; Gleave, Martin; Halabi, Susan; Heinrich, Daniel; Higano, Celestia; Hofman, Michael S; Hussain, Maha; James, Nicholas; Jones, Rob; Kanesvaran, Ravindran; Khauli, Raja B; Klotz, Laurence; Leibowitz, Raya; Logothetis, Christopher; Maluf, Fernando; Millman, Robin; Morgans, Alicia K; Morris, Michael J; Mottet, Nicolas; Mrabti, Hind; Murphy, Declan G; Murthy, Vedang; Oh, William K; Ekeke Onyeanunam, Ngozi; Ost, Piet.
  • Turco F; Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Division of Medical Oncology, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy. Electronic address: turcofabio9@gmail.com.
  • Armstrong A; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA.
  • Attard G; University College London Cancer Institute, London, UK.
  • Beer TM; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
  • Beltran H; Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Bjartell A; Department of Urology, Skåne University Hospital, Malmö, Sweden.
  • Bossi A; Genito Urinary Oncology, Prostate Brachytherapy Unit, Goustave Roussy, Paris, France.
  • Briganti A; Unit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
  • Bristow RG; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Christie NHS Trust and CRUK Manchester Institute and Cancer Centre, Manchester, UK.
  • Bulbul M; Division of Urology, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon.
  • Caffo O; Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy.
  • Chi KN; BC Cancer, Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.
  • Clarke C; Research Department of Primary Care & Population Health, Royal Free Campus, University College London, Rowland Hill St, London, UK.
  • Clarke N; The Christie and Salford Royal Hospitals, Manchester, UK.
  • Davis ID; Monash University and Eastern Health, Victoria, Australia.
  • de Bono J; The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Surrey, UK.
  • Duran I; Department of Medical Oncology. Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Cantabria, Spain.
  • Eeles R; The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.
  • Efstathiou E; Houston Methodist Cancer Center, Houston, TX, USA.
  • Efstathiou J; Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.
  • Evans CP; University of California Davis School of Medicine, Sacramento, CA, USA.
  • Fanti S; Policlinico S. Orsola, Università di Bologna, Bologna, Italy.
  • Feng FY; University of California, San Francisco, San Francisco, CA, USA.
  • Fizazi K; Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.
  • Frydenberg M; Department of Surgery, Monash University, Melbourne, Australia; Prostate Cancer Research Program, Department of Anatomy & Developmental Biology, Faculty of Nursing, Medicine & Health Sciences, Monash University, Melbourne, Australia.
  • George D; Departments of Medicine and Surgery, Duke Cancer Institute, Duke University, Durham, NC, USA.
  • Gleave M; Urological Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada.
  • Halabi S; Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.
  • Heinrich D; Department of Oncology and Radiotherapy, Innlandet Hospital Trust, Gjøvik, Norway.
  • Higano C; University of British Columbia, Vancouver, British Columbia, Canada.
  • Hofman MS; Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
  • Hussain M; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
  • James N; The Institute of Cancer Research, London, UK.
  • Jones R; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Kanesvaran R; Division of Medical Oncology, National Cancer Centre, Singapore.
  • Khauli RB; Department of Urology and the Naef K. Basile Cancer Institute (NKBCI), American University of Beirut Medical Center, Beirut, Lebanon.
  • Klotz L; Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
  • Leibowitz R; Oncology institute, Shamir Medical Center, Zerifin, Israel; Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Logothetis C; Department of Genitourinary Medical Oncology, MD Anderson Cancer Centre, Houston, TX, USA; Department of Clinical Therapeutics, Alexandra Hospital, University of Athens, Athens, Greece; David H. Koch Centre, Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer
  • Maluf F; Beneficiência Portuguesa de São Paulo, São Paulo, SP, Brazil; Departamento de Oncologia, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
  • Millman R; Patient Advocate, UK.
  • Morgans AK; Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Morris MJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Mottet N; University Hospital Nord St Etienne, St Etienne, France.
  • Mrabti H; National Institute of Oncology, University hospital, Rabat, Morocco.
  • Murphy DG; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.
  • Murthy V; Tata Memorial Centre, Mumbai, India.
  • Oh WK; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA.
  • Ekeke Onyeanunam N; Department of Surgery, University of Port Harcourt Teaching Hospital, Alakahia, Port Harcourt, Nigeria.
  • Ost P; Department of Radiation Oncology, Iridium Netwerk, Wilrijk (Antwerp), Belgium; Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
Eur Urol ; 82(1): 6-11, 2022 07.
Article in English | MEDLINE | ID: covidwho-1768076
ABSTRACT
Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, or comorbidities. Thus, the optimal management of APC patients during the COVID-19 pandemic is complex. In October 2021, during the Advanced Prostate Cancer Consensus Conference (APCCC) 2021, the 73 voting members of the panel members discussed and voted on 13 questions on this topic that could help clinicians make treatment choices during the pandemic. There was a consensus for full COVID-19 vaccination and booster injection in APC patients. Furthermore, the voting results indicate that the expert's treatment recommendations are influenced by the vaccination status the COVID-19 pandemic altered management of APC patients for 70% of the panellists before the vaccination was available but only for 25% of panellists for fully vaccinated patients. Most experts (71%) were less likely to use docetaxel and abiraterone in unvaccinated patients with metastatic hormone-sensitive prostate cancer. For fully vaccinated patients with high-risk localised prostate cancer, there was a consensus (77%) to follow the usual treatment schedule, whereas in unvaccinated patients, 55% of the panel members voted for deferring radiation therapy. Finally, there was a strong consensus for the use of telemedicine for monitoring APC patients. PATIENT

SUMMARY:

In the Advanced Prostate Cancer Consensus Conference 2021, the panellists reached a consensus regarding the recommendation of the COVID-19 vaccine in prostate cancer patients and use of telemedicine for monitoring these patients.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Prostatic Neoplasms / COVID-19 Type of study: Prognostic study Topics: Vaccines Limits: Humans / Male Language: English Journal: Eur Urol Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Prostatic Neoplasms / COVID-19 Type of study: Prognostic study Topics: Vaccines Limits: Humans / Male Language: English Journal: Eur Urol Year: 2022 Document Type: Article